Collaborative Medicinal Development Pty Limited: Clinical Trials

6 trials sponsored by Collaborative Medicinal Development Pty Limited, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 unknown. 4 Phase 1, 3 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 14Completed 3, Unknown 1
Phase 23Unknown 2, Completed 1
Phase 31Unknown 1

Follow Collaborative Medicinal Development Pty Limited: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001
Cu(II)ATSM - Amyotrophic Lateral Sclerosis
Phase 2CompletedCollaborative Medicinal Development Pty Limited552020-03-192022-02-17
CuATSM Compared With Placebo for Treatment of ALS/MND
Cu(II)ATSM, Placebos - Amyotrophic Lateral Sclerosis
Phase 2 / Phase 3UnknownCollaborative Medicinal Development Pty Limited802019-09-302019-11-06
ALS Treatment Extension Study
Cu(II)ATSM - Amyotrophic Lateral Sclerosis
Phase 1 / Phase 2UnknownCollaborative Medicinal Development Pty Limited282018-01-182022-02-17
Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease
Cu(II)ATSM - Parkinson Disease
Phase 1CompletedCollaborative Medicinal Development Pty Limited312017-08-142020-03-17
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND
Cu(II)ATSM - Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Phase 1CompletedCollaborative Medicinal Development Pty Limited502016-11-162020-03-17
Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors
DpC - Neoplasms
Phase 1CompletedCollaborative Medicinal Development Pty Limited142016-04-112019-02-21

Conditions studied

Amyotrophic Lateral Sclerosis (4)  ·  Motor Neuron Disease (1)  ·  Neoplasms (1)  ·  Parkinson Disease (1)

Interventions

copper (II) diacetyl-di(N(4)-methylthiosemicarbazone) (5)  ·  Copper (4)  ·  di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (1)

Countries

Australia (6)

Top investigators

Dominic Rowe, MD (4)  ·  Andrew Evans, MD (1)  ·  Linda Mileshkin, MD (1)